KRYS — Krystal Biotech Share News
0.000.00%
Last trade - 00:00- $9.77bn
- $8.92bn
- $389.13m
U.S. RESEARCH ROUNDUP-Aerovironment, Hubspot, Oracle
Brief: Krystal Biotech Announces Orphan Drug Designation Granted To KB408 For The Treatment Of Alpha-1 Antitrypsin Deficiency
Brief: Krystal Biotech Announces Sale Of Priority Review Voucher For $100 Mln
Krystal Biotech Inc reports results for the quarter ended in June - Earnings Summary
Brief: Krystal Biotech Q2 Net Income USD -33.21 Million
Krystal Biotech Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Krystal Biotech Announces Pipeline Expansion Into Oncology And FDA Acceptance Of Ind Application For Lead Oncology Candidate KB707
Brief: Krystal Biotech Announces Pipeline Expansion Into Oncology And FDA Acceptance Of Ind Application
Brief: Krystal Biotech Announces First Patient Dosed In Phase 1 Clinical Trial Of KB407 For The Treatment Of Cystic Fibrosis
Brief: Option Care Health Selected For VYJUVEK By Krystal Biotech
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
Krystal gains as brokerages raise PT on FDA nod for skin-disorder gene therapy
Krystal Biotech rises on FDA nod for skin disorder gene therapy
U.S. FDA approves Krystal Biotech's skin disorder gene therapy (updated)
Brief: Krystal Biotech Receives FDA Approval For Vyjuvek
U.S. FDA approves Krystal Biotech's skin disorder gene therapy
Brief: U.S. FDA Approves First Topical Gene Therapy For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa
SEC Filing